Project Grant R13AI186428

Award Date 8/6/24
Completion Date 7/31/25
Dollars Obligated $5K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Doylestown, PA 18901, USA
Similar Awards
The National Institutes of Health (NIH), through its Trans-NIH Research Support program (CFDA 93.310), has awarded a $800,000 Project Grant to the International AIDS Society (IAS) to support the 13th IAS Conference on HIV Science, which will be held in Kigali, Rwanda from July 14-17, 2025. This major international conference is expected to attract approximately 6,000 participants and will serve as a platform to catalyze action based on the latest cutting-edge HIV research. The grant funding will...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...
This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the mechanisms underlying hepatitis delta virus (HDV) pathogenesis. The $249,000 award to the University of Southern California aims to: 1) Determine the proviral role of the MDA5 signaling pathway in HDV infection, and 2) Define the mechanism of HDV-induced hepatocyte programmed cell death. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $673,158 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a proteomics atlas of HIV/HBV co-infections for advancing HBV cure strategies. The project aims to use robust co-culture systems, CRISPR screens, and multi-omics approaches in primary human hepatocytes and CD4+ T cells to discover and validate host factors and antivirals against HIV/HBV...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,512.00 to Emory University to investigate the role of intrahepatic (liver-resident) plasma cells in clearing hepatitis C virus (HCV) infection. The goal is to characterize the mechanistic origins of these plasma cells and determine if they are primed locally within the liver or follow traditional homing...

2024 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES (INTERNATIONAL HBV MEETING) - ABSTRACT/SUMMARY HEPATITIS B VIRUS (HBV) IS A MAJOR GLOBAL PUBLIC HEALTH THREAT WITH APPROXIMATELY 296 MILLION CHRONICALLY INFECTED PEOPLE WORLDWIDE AND OVER 800,000 DEATHS PER YEAR. CHRONIC HBV INFECTION IS A LEADING CAUSE FOR DEVELOPMENT OF LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. DESPITE THE EFFECTIVENESS OF THE PROPHYLACTIC HBV VACCINE, IT HAS NO IMPACT ON ESTABLISHED CHRONIC INFECTIONS. CONSEQUENTLY, THERE IS A GREAT NEED TO DISCOVER NEW THERAPEUTIC STRATEGIES TO CURE CHRONIC HBV INFECTION AND SLOW OR STOP THE RESULTING DISEASE. THE ANNUAL INTERNATIONAL HBV MEETING IS THE ONLY FORUM THAT GATHERS THE INTERNATIONAL COMMUNITY OF RESEARCHERS WHO STUDY INFECTION, PERSISTENCE, PATHOGENESIS, AND DRUG DEVELOPMENT FOR HBV AND THE CLOSELY ASSOCIATED HEPATITIS DELTA VIRUS (HDV). THIS INTERNATIONAL HBV MEETING HAS BEEN HELD YEARLY SINCE 1985 AND HAS BEEN ROTATING BETWEEN THE US, EUROPE, EAST ASIA AND AUSTRALIA. IN 2024, THIS MEETING WILL BE HELD CHICAGO, IL, IN 2025 IN EUROPE AND THE MEETING SITE FOR 2026 WILL BE DETERMINED NEXT YEAR. SUCCESS OF THE INTERNATIONAL HBV MEETING RELIES ON THE CONTRIBUTIONS OF NOT ONLY THE ESTABLISHED INVESTIGATORS, BUT IMPORTANTLY, ALSO ON EARLY CAREER RESEARCHERS FROM DIVERSE BACKGROUNDS. TO FACILITATE THE PARTICIPATION OF YOUNG SCIENTISTS, WE REQUEST FUNDING TO SUPPORT TRAVEL EXPENSES FOR EARLY CAREER AND UNDER- REPRESENTED RESEARCHERS AT THE 2024, 2025 AND 2026 INTERNATIONAL HBV MEETINGS. THE 2024 MEETING WILL PROVIDE THE OPPORTUNITY FOR SCIENTIFIC EXCHANGE AND DISSEMINATION OF THE LATEST RESEARCH INFORMATION TO DISCOVER NEW STRATEGIES FOR POTENTIALLY CURING HBV AND HDV. AN ESTIMATED 500-600 DELEGATES WILL ATTEND THE 2024 MEETING. THE MEETING WILL CONSIST OF 10 ORAL SCIENTIFIC SESSIONS, 2 POSTER SESSIONS, 3 PLENARY LECTURES FROM EXPERTS OUTSIDE OF THE HBV FIELD WHO WILL BRING DIFFERENT PERSPECTIVES, AND A LECTURE GIVEN BY THE RECIPIENT OF THE DISTINGUISHED AWARD IN HBV RESEARCH THAT IS AWARDED ANNUALLY BY THE MEETING. TOWARD THE GOAL OF CURING HBV AND HDV, THIS MEETING WILL HOST A HBV CURE SATELLITE SYMPOSIUM TO DISCUSS MECHANISMS OF ANTIVIRAL THERAPIES, AND BY AN HBV COMMUNITY FORUM WHERE SCIENTISTS FROM THE HBV COMMUNITY ENGAGE WITH THE GENERAL PUBLIC, MEDIA, STUDENTS AND THOSE AFFECTED BY HBV TO DISCUSS HBV/HDV AND THE RELATED DISEASES. AS IN THE PAST, GREAT EFFORT HAS BEEN MADE TO MINIMIZE THE COST OF THE MEETING. A MAJOR STRENGTH OF THE MEETING ORGANIZATION BEING CONTINUAL SUPPORT FROM THE HEPATITIS B FOUNDATION SINCE 2005. TO ENABLE AND FACILITATE PARTICIPATION OF EARLY CAREER RESEARCHERS AND UNDER-REPRESENTED MINORITY INVESTIGATORS TO MAXIMIZE THE SIGNIFICANCE OF THE MEETING, WE REQUEST SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH TO HELP DEFRAY THEIR TRAVEL COSTS. THIS FUNDING WILL BE USED TO ENSURE ATTENDANCE AND PRESENTATION BY EARLY CAREER RESEARCHERS, PARTICULARLY FROM LOW AND MIDDLE-INCOME COUNTRIES, AS WELL AS DISADVANTAGED AND UNDER-REPRESENTED MINORITY INVESTIGATORS.

Posted 8/6/24